In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment

Chronic HCV infection is characterized by several immunological alterations, such as the accumulation of suppressor cells and of hyperactivated T lymphocytes. However, it is unclear whether direct-acting antiviral (DAA)-mediated HCV clearance restores immune dysfunctions. We performed a phenotypic c...

Full description

Bibliographic Details
Main Authors: Valentina Telatin, Francesco Nicoli, Chiara Frasson, Nicola Menegotto, Francesco Barbaro, Eleonora Castelli, Elke Erne, Giorgio Palù, Antonella Caputo
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
HCV
DAA
Online Access:https://www.frontiersin.org/article/10.3389/fcimb.2019.00190/full
id doaj-720cc52a9c5c43198976066e414ff35b
record_format Article
spelling doaj-720cc52a9c5c43198976066e414ff35b2020-11-25T01:48:29ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882019-06-01910.3389/fcimb.2019.00190455712In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral TreatmentValentina Telatin0Francesco Nicoli1Chiara Frasson2Nicola Menegotto3Francesco Barbaro4Eleonora Castelli5Elke Erne6Giorgio Palù7Antonella Caputo8Department of Molecular Medicine, University of Padova, Padova, ItalyDepartment of Molecular Medicine, University of Padova, Padova, ItalyIstituto di Ricerca Pediatrica (IRP) Città della Speranza, Padova, ItalyDepartment of Molecular Medicine, University of Padova, Padova, ItalyInfectious and Tropical Diseases Unit, Azienda Ospedaliera di Padova, Padova, ItalyInfectious and Tropical Diseases Unit, Azienda Ospedaliera di Padova, Padova, ItalyInfectious and Tropical Diseases Unit, Azienda Ospedaliera di Padova, Padova, ItalyDepartment of Molecular Medicine, University of Padova, Padova, ItalyDepartment of Molecular Medicine, University of Padova, Padova, ItalyChronic HCV infection is characterized by several immunological alterations, such as the accumulation of suppressor cells and of hyperactivated T lymphocytes. However, it is unclear whether direct-acting antiviral (DAA)-mediated HCV clearance restores immune dysfunctions. We performed a phenotypic characterization by flow cytometry of different immune cell subsets, including monocytic myeloid-derived suppressor cells (M-MDSCs) and T lymphocytes in 168 patients with persistent HCV infection not treated, under DAA therapies and sustained virological responders. Chronic HCV infection prompted the accumulation of M-MDSCs independently of patient and clinical characteristics, and altered their metabolic properties. HCV RNA was undetectable in the majority of patients just after few weeks of DAA therapy, whereas M-MDSC levels normalized only 6 months after therapy. In addition, HCV infection deeply perturbed the T cell compartment since a re-distribution of memory CD4+ and CD8+ T cells was observed at the expenses of naïve cells, and memory T lymphocytes displayed increased activation. Notably, these features were only partially restored by DAA therapies in the CD4, but not in the CD8, compartment as high immune activation levels persisted in the terminally differentiated memory CD8+ T cells even more than 1 year after sustained virological response. Together, these results suggest that successful DAA therapies do not lead to full immunological reconstitution as fast as viral clearance.https://www.frontiersin.org/article/10.3389/fcimb.2019.00190/fullHCVDAAM-MDCSsTregsT lymphocytes
collection DOAJ
language English
format Article
sources DOAJ
author Valentina Telatin
Francesco Nicoli
Chiara Frasson
Nicola Menegotto
Francesco Barbaro
Eleonora Castelli
Elke Erne
Giorgio Palù
Antonella Caputo
spellingShingle Valentina Telatin
Francesco Nicoli
Chiara Frasson
Nicola Menegotto
Francesco Barbaro
Eleonora Castelli
Elke Erne
Giorgio Palù
Antonella Caputo
In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment
Frontiers in Cellular and Infection Microbiology
HCV
DAA
M-MDCSs
Tregs
T lymphocytes
author_facet Valentina Telatin
Francesco Nicoli
Chiara Frasson
Nicola Menegotto
Francesco Barbaro
Eleonora Castelli
Elke Erne
Giorgio Palù
Antonella Caputo
author_sort Valentina Telatin
title In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment
title_short In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment
title_full In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment
title_fullStr In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment
title_full_unstemmed In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment
title_sort in chronic hepatitis c infection, myeloid-derived suppressor cell accumulation and t cell dysfunctions revert partially and late after successful direct-acting antiviral treatment
publisher Frontiers Media S.A.
series Frontiers in Cellular and Infection Microbiology
issn 2235-2988
publishDate 2019-06-01
description Chronic HCV infection is characterized by several immunological alterations, such as the accumulation of suppressor cells and of hyperactivated T lymphocytes. However, it is unclear whether direct-acting antiviral (DAA)-mediated HCV clearance restores immune dysfunctions. We performed a phenotypic characterization by flow cytometry of different immune cell subsets, including monocytic myeloid-derived suppressor cells (M-MDSCs) and T lymphocytes in 168 patients with persistent HCV infection not treated, under DAA therapies and sustained virological responders. Chronic HCV infection prompted the accumulation of M-MDSCs independently of patient and clinical characteristics, and altered their metabolic properties. HCV RNA was undetectable in the majority of patients just after few weeks of DAA therapy, whereas M-MDSC levels normalized only 6 months after therapy. In addition, HCV infection deeply perturbed the T cell compartment since a re-distribution of memory CD4+ and CD8+ T cells was observed at the expenses of naïve cells, and memory T lymphocytes displayed increased activation. Notably, these features were only partially restored by DAA therapies in the CD4, but not in the CD8, compartment as high immune activation levels persisted in the terminally differentiated memory CD8+ T cells even more than 1 year after sustained virological response. Together, these results suggest that successful DAA therapies do not lead to full immunological reconstitution as fast as viral clearance.
topic HCV
DAA
M-MDCSs
Tregs
T lymphocytes
url https://www.frontiersin.org/article/10.3389/fcimb.2019.00190/full
work_keys_str_mv AT valentinatelatin inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
AT francesconicoli inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
AT chiarafrasson inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
AT nicolamenegotto inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
AT francescobarbaro inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
AT eleonoracastelli inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
AT elkeerne inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
AT giorgiopalu inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
AT antonellacaputo inchronichepatitiscinfectionmyeloidderivedsuppressorcellaccumulationandtcelldysfunctionsrevertpartiallyandlateaftersuccessfuldirectactingantiviraltreatment
_version_ 1725011864032641024